Search Results

GCSFs might be considered in patients with severe neutropenic fever after chemotherapy. HBV Reactivation: HBV reactivation leading to fulminant hepatitis, hepatic failure, and death have been reported in patients receiving chemotherapy and

be given in 1 to 4 injections for children with iron-deficiency anemia. This method was appealing to clinicians because the reported incidence of reactions was on the order of only 1% and included symptoms such as fever, arthralgia, and

cancer survivors between time points and distress the areas of eating ( P <.04), fatigue ( P <.01), fevers ( P <.02), getting around ( P <.05), mouth sores ( P <.05), congestion ( P <.02), sleep ( P <.02), fears ( P =.05), nervousness ( P =.04), physical

woman presented with several weeks of progressive fatigue, bruising, and eventually the development of fevers. She had no prior medical problems and took no medications. Physical examination revealed only moderate splenomegaly, measuring 14 cm. On

, dysphagia, or dyspnea. He reported no significant weight loss, fevers, or chills, and had not noticed any other masses or unusual skin lesions. He did report mild fatigue. A brief trial of antibiotics was prescribed by a primary care physician but did not

56-year-old woman noted a slowly enlarging right parotid mass for approximately 2 months. She denied any fever, night sweats, decreased salivation, dry eyes, pain, or facial paresthesias. She had an intentional weight loss of about 19 pounds over the

Mulago Hospital reporting a 7-year history of gradually increasing pruritus and diffuse, scaly skin lesions ( Figure 1A ). More recently he reported mild weight loss and anorexia, although he denied having drenching night-sweats or fevers. He denied any

onset abdominal pain and fevers, and imaging results were concerning for abscess formation at the anastomotic site. He underwent exploratory laparotomy, ileocolostomy resection, and abdominal washout with wide drainage for ileocolostomy perforation

abdominal pain resolved after recent administration of a proton pump inhibitor. She denied gastrointestinal symptoms. She denied melena, nausea, vomiting, anorexia, unintentional weight loss, fevers, and night sweats. Her medical history was notable for HT

to a nadir of 385 ng/mL at the time of disease progression. The patient’s treatment course was complicated by rash and fevers, which required low doses of prednisone and reduced doses of dabrafenib (100 mg orally twice daily) and trametinib (1.5 mg